Across rheumatic diseases

Perceived Impacts and Predictors of Cannabis Products Used by Patients with Rheumatologic Conditions in Alberta, Canada: A Multivariable Analysis of Cross‐Sectional Survey Data

Arthritis Care Res (Hoboken)Published Cross-sectional study

Authors' conclusion

There is significant variability in cannabis products used by patients with rheumatologic conditions, who are influenced by patient-specific factors.

Study context

Population
Patients with rheumatologic conditions in Alberta, Canada, who use cannabis; online survey March–November 2022cannabis users analysed
Participants
1,436 patients
Exposure
Cannabis products by cannabinoid content and formulation
Outcome
Composite positive impact score (eg, pain, sleep, mood) and side effects (CNS-activating, dampening, sensory) by cannabis product choice
Methodological detailsonline survey, multivariable analysis
  • Online survey
  • Multivariable analysis

Main finding

As reported in the abstract

Higher positive impact scores
Adjusted odds ratio (95% CI)
THC-CBD-balanced
1.76(1.18–2.63)
Dried cannabis
1.86(1.07–3.23)
Edibles
2.18(1.41–3.37)

Observational data: associations, not effects.

Further findings

Determinants of cannabis product choice

Product choice varied by age, gender, comorbidities, prior cannabis experience, frequency of use, reasons for use, access to cannabis prescription, and source of cannabis information

Safety

High dampening side effects

aOR (95% CI)
THC-dominant1.85 (1.16–2.98)
Dried cannabis1.98 (1.19–3.27)

High sensory side effects

aOR (95% CI)
THC-dominant2.16 (1.27–3.70)
Dried cannabis3.05 (1.67–5.58)

Original publication

Perceived Impacts and Predictors of Cannabis Products Used by Patients with Rheumatologic Conditions in Alberta, Canada: A Multivariable Analysis of Cross‐Sectional Survey Data. Arthritis Care Res (Hoboken). Published 10 June 2026. doi:10.1002/acr.80071

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.